Pfizer report:

1) We felt the numbers were very good. The EPS shows promising groth

into 2000, and the ranking from Merrill of A-2-1 is also great. The stock

performance has been for the main part an upward trend, with a 52 week

high of about $50.

2) Pfizer is a leader in their field. Their main competitor is

Merck but with the introduction of Viagra, Pfizer has gained a lot of

publicity and is thus becoming the leader in Pharmaceuticals.

3) Their new products include Tikosyn, an anti-arrhythmic drug.

Pfizer is continually innovating to create new products that can target a

wide variety of people, such as the "baby boomers" who are now approaching

their mid-50s and 60s.

4) Our feeling is that Pfizer is a good stock to hold as a possible

anchor in our portfolio. We feel that in the short term period that we

are looking to invest in it may not be very agressive. But we feel it is

rather secure and a safe bet.

5) Buy trigger: $35 or current price

Sell trigger: below $30